Prostate cancer is the second-leading cause of death in American men. However, prostate cancer is curable, thanks to options ...

Prostate cancer incidence in the US shows a concerning rise, particularly in advanced stages. While early prostate cancer ...

Higher BMI was associated with improved survival among patients with prostate cancer, especially those with metastatic disease.

A new study from the American Cancer Society (ACS) reports that men diagnosed with non-metastatic prostate cancer who adopted ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits ...

In the discussion, Petrylak highlighted advances in identifying genetic mutations and emerging strategies for early, ...

In the phase 2 EXTEND trial, investigators randomly assigned patients with oligometastatic prostate cancer to ADT or MDT + ADT, with further stratification by intermittent vs continuous ADT that was ...

The global hormone sensitive advanced prostate cancer (HSPC) market is witnessing substantial growth due to rising prostate cancer cases, advancements in hormonal and combination treatments, and ...

Median progression-free survival (PFS) increased from 7.4 months with stereotactic body radiotherapy (SBRT) to 17.6 months with the addition of 177 lutetium (Lu) PNT2002 targeting prostate-specific ...

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 ...